Cargando…

Pacritinib abrogates the lupus phenotype in ABIN1[D485N] mice

OBJECTIVE: The aim of the study was to investigate whether the IRAK1/JAK2/Flt3 inhibitor pacritinib prevents disease development in the lupus-prone ABIN1[D485N] knock-in mouse. METHODS: ABIN1[D485N] knock-in mice aged 8 weeks were fed for 10 weeks on a diet containing pacritinib. Body weight was mon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petrova, Tsvetana, Figueras-Vadillo, Clara, Nanda, Sambit K, Scudamore, Cheryl, Cohen, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950973/ https://www.ncbi.nlm.nih.gov/pubmed/36822800 http://dx.doi.org/10.1136/lupus-2022-000822

Ejemplares similares

Prevention and partial reversion of the lupus phenotype in ABIN1[D485N] mice by an IRAK4 inhibitor
por: Petrova, Tsvetana, et al.
Publicado: (2021)

Distinct signals and immune cells drive liver pathology and glomerulonephritis in ABIN1[D485N] mice
por: Nanda, Sambit Kumar, et al.
Publicado: (2019)

An important role for A20-binding inhibitor of nuclear factor-kB-1 (ABIN1) in inflammation-mediated endothelial dysfunction: an in vivo study in ABIN1 (D485N) mice
por: Akbar, Naveed, et al.
Publicado: (2015)

Why are the phenotypes of TRAF6 knock-in and TRAF6 knock-out mice so different?
por: Petrova, Tsvetana, et al.
Publicado: (2022)

Polyubiquitin binding to ABIN1 is required to prevent autoimmunity
por: Nanda, Sambit K., et al.
Publicado: (2011)

Suppression of IRAK1 or IRAK4 Catalytic Activity, but Not Type 1 IFN Signaling, Prevents Lupus Nephritis in Mice Expressing a Ubiquitin Binding–Defective Mutant of ABIN1
por: Nanda, Sambit K., et al.
Publicado: (2016)

IKKβ is required for the formation of the NLRP3 inflammasome
por: Nanda, Sambit K, et al.
Publicado: (2021)

TNIP1/ABIN1 and lupus nephritis: review
por: Brady, Makayla P, et al.
Publicado: (2020)

The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

Emerging treatment options for myelofibrosis: focus on pacritinib
por: Chow, Vivian, et al.
Publicado: (2016)

Profile of pacritinib and its potential in the treatment of hematologic disorders
por: Hatzimichael, Eleftheria, et al.
Publicado: (2014)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Expression and role of ABIN1 in sepsis: In vitro and in vivo studies
por: Li, Haolan, et al.
Publicado: (2020)

Expression and role of ABIN1 in sepsis: In vitro and in vivo studies
por: Li, Haolan, et al.
Publicado: (2022)

A20 and ABIN-1 synergistically preserve intestinal epithelial cell survival
por: Kattah, Michael G., et al.
Publicado: (2018)

ABIN-1 is a key regulator in RIPK1-dependent apoptosis (RDA) and necroptosis, and ABIN-1 deficiency potentiates necroptosis-based cancer therapy in colorectal cancer
por: Cai, Jiali, et al.
Publicado: (2021)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures
por: Singer, Jack W., et al.
Publicado: (2019)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
por: Vannucchi, A., et al.
Publicado: (2022)

ABIN1 Inhibits Inflammation through Necroptosis-Dependent Pathway in Ulcerative Colitis
por: Bao, Jing, et al.
Publicado: (2022)

Symphonie no. 5 D485 Symphonie no. 6 D485 /
por: Schubert, Franz, 1797-1828
Publicado: (1988)

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
por: Singer, Jack W, et al.
Publicado: (2016)

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
por: Torres, Sandra, et al.
Publicado: (2023)

Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib
por: Yacoub, Abdulraheem, et al.
Publicado: (2023)

ABIN-1 is a Ubiquitin Sensor that Restricts Cell Death and Sustains Embryonic Development
por: Oshima, Shigeru, et al.
Publicado: (2008)

A20 and ABIN-1 team up against intestinal epithelial cell death
por: Cadwell, Ken
Publicado: (2018)

ABIN1 alleviates inflammatory responses and colitis via facilitating A20 activity
por: Pu, Tian, et al.
Publicado: (2020)

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis
por: Harrison, Claire, et al.
Publicado: (2023)

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
por: Oh, Stephen T., et al.
Publicado: (2023)

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS
por: Gagelmann, Nico, et al.
Publicado: (2023)

TAK1 protein kinase activity is required for TLR signalling and cytokine production in myeloid cells
por: Rodrigues, Melissa, et al.
Publicado: (2022)

HOIL‐1 ubiquitin ligase activity targets unbranched glucosaccharides and is required to prevent polyglucosan accumulation
por: Kelsall, Ian R, et al.
Publicado: (2022)

P987: IRAK1 AND JAK2 DUAL INHIBITION WITH PACRITINIB PREVENTS MYELOFIBROSIS-LIKE PHENOTYPE IN AN INFLAMMATION-DRIVEN MURINE MODEL
por: Zamora, Ernesto José Cuenca, et al.
Publicado: (2023)

Immune regulator ABIN1 suppresses HIV-1 transcription by negatively regulating the ubiquitination of Tat
por: Chen, Shiyou, et al.
Publicado: (2017)

Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis
por: Al-Fayoumi, Suliman, et al.
Publicado: (2018)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
por: Harrison, C., et al.
Publicado: (2022)

Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3
por: Ghezzi, Chiara, et al.
Publicado: (2023)

Immunosuppression abrogates resistance of young rabbits to Rabbit Haemorrhagic Disease (RHD)
por: Marques, Raquel M, et al.
Publicado: (2014)

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
por: Hart, S, et al.
Publicado: (2011)

P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS
por: Masarova, Lucia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_is1hu8069dg0kva57r083qj9jo